Effects of denosumab followed by zoledronate on BMD in postmenopausal... | Download Scientific Diagram
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial - The Lancet
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis | NEJM
Comparison of the efficacy between sequential therapy with teriparatide and denosumab and denosumab monotherapy in suppressing fragility fracture risk | SpringerLink
Denosumab – die reversible Wirksamkeit im klinischen Fokus Denosumab – the reversible efficacy in the clinical focus
New and emerging concepts in the use of denosumab for the treatment of osteoporosis - E. Michael Lewiecki, 2018
WO2013181575A2 - Methods related to denosumab - Google Patents
Figures and data in Modeling osteoporosis to design and optimize pharmacological therapies comprising multiple drug types | eLife
The effect of osteoporosis treatment on bone mass - ScienceDirect
Adherence, Preference, & Satisfaction Study | Prolia® (denosumab)
Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab | SpringerLink
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab | Nature Reviews Drug Discovery
Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL | Oncotarget
Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review | SpringerLink
Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone | Nature Reviews Rheumatology
Cancers | Free Full-Text | Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence
Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review | SpringerLink
Frontiers | A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial
JCM | Free Full-Text | Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
Long-term follow up after denosumab treatment for osteoporosis – rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report | Journal of Medical Case Reports
Long-term consequences of osteoporosis therapy with denosumab - Archives of Endocrinology and Metabolism
DB06643 Denosumab C6404H9912N1724O2004S kDa CATEGORY - ppt download
